Ebola disease Diagnostics

Introduction: When to Seek Diagnostic Testing

If you have recently traveled to or lived in regions of Central or West Africa where Ebola disease outbreaks have occurred, and you begin to feel unwell, it is important to seek medical attention promptly. Ebola disease is a serious viral infection that requires early identification to ensure proper care and prevent spread to others. Anyone who has been in contact with someone diagnosed with Ebola disease, or who has touched the body fluids of an infected person or animal, should be evaluated even before symptoms appear.1

Healthcare providers and family members who have cared for Ebola patients without proper protective equipment are at the highest risk and should undergo diagnostic screening immediately if they develop any concerning symptoms. The viruses that cause Ebola disease pose little risk to travelers or the general public, but those with specific exposures need to be monitored closely. Because the disease can progress rapidly from mild flu-like symptoms to severe illness, timely diagnosis is critical for both the patient's survival and to protect the community.1

Symptoms typically begin between 2 and 21 days after exposure to the virus, though most people start feeling sick around 8 to 10 days after contact. Early symptoms often include fever, severe headache, muscle pain, weakness, and fatigue. These initial signs can easily be mistaken for more common illnesses like malaria or the flu. As the disease advances, patients may develop diarrhea, vomiting, stomach pain, and in later stages, unexplained bleeding. Anyone experiencing these symptoms within three weeks of potential Ebola exposure should contact a healthcare provider immediately and explain their travel history or contact with infected individuals.1

Diagnostic Methods Used to Identify Ebola Disease

Diagnosing Ebola disease begins with a thorough assessment of the patient's recent travel history, potential exposure to infected individuals or animals, and current symptoms. Healthcare providers must ask detailed questions about where the person has been in the past three weeks, whether they attended any funeral ceremonies, had contact with sick people or animals, or worked in healthcare settings where Ebola patients were treated. This information helps doctors determine if Ebola testing is necessary or if other more common illnesses should be considered first.2

When Ebola disease is suspected, the most definitive way to confirm the diagnosis is through laboratory blood tests that detect the presence of the virus or the body's response to it. The primary diagnostic test is called reverse transcription-polymerase chain reaction, or RT-PCR for short. This test looks for the genetic material of the virus in a blood sample. RT-PCR can identify the virus's ribonucleic acid, which is the genetic blueprint that the virus uses to make copies of itself inside human cells. This test is highly sensitive and can detect even small amounts of the virus in the bloodstream.3

However, timing matters greatly when testing for Ebola disease. The virus may not show up in blood tests during the very early stages of illness, particularly in the first three days after symptoms begin. For this reason, if the first test comes back negative but the patient still has symptoms and a history of exposure, healthcare providers may repeat the test a few days later. This approach helps avoid missing a case due to testing too early in the infection.2

In addition to RT-PCR, there are other laboratory methods that can help diagnose Ebola disease. Blood tests can detect specific proteins called antigens that are part of the virus structure. Another approach looks for antibodies, which are proteins that the body's immune system produces in response to the infection. These antibodies typically appear later in the illness, so antibody tests are more useful for confirming that someone had Ebola in the past rather than diagnosing an active, ongoing infection.4

Viral culture is another diagnostic method where laboratory specialists try to grow the virus from a patient's blood sample. When the virus successfully grows in the laboratory, it provides definitive proof of infection. However, this technique requires specialized high-security laboratories and takes more time than RT-PCR testing, so it is less commonly used for immediate diagnosis. Viral culture is most often performed in research settings or to confirm unusual cases.3

Healthcare providers may also order additional blood tests to check how the infection is affecting the patient's body. A complete blood count can reveal abnormalities in white blood cells, which are part of the immune system, or in platelets, which help blood to clot. Blood chemistry tests can show how well the liver and kidneys are functioning, since Ebola virus can damage these organs. These tests do not diagnose Ebola directly, but they help doctors understand the severity of the illness and guide treatment decisions.2

It is crucial to understand that diagnosing Ebola disease involves ruling out other illnesses that have similar symptoms. In regions where Ebola occurs, many other infectious diseases are far more common. Malaria, typhoid fever, influenza, and even gastroenteritis can cause fever, body aches, and fatigue just like Ebola. Healthcare providers typically test for these more common conditions at the same time they evaluate for Ebola. Timely identification of other likely causes helps ensure patients receive appropriate treatment while waiting for Ebola test results.2

Safety precautions during the diagnostic process are extremely important. All healthcare workers who collect blood samples or handle specimens from patients with suspected Ebola disease must wear proper personal protective equipment, or PPE. This includes gloves, gowns, masks, and eye protection to prevent contact with potentially infectious body fluids. Samples must be transported in secure, leak-proof containers to specialized laboratories that have the facilities to safely test for dangerous pathogens.1

Diagnostic Testing for Clinical Trial Qualification

When patients with Ebola disease are considered for enrollment in clinical trials testing new treatments or vaccines, they must undergo specific diagnostic procedures to determine their eligibility. Clinical trials typically have strict criteria about who can participate, and accurate testing is essential to ensure that only appropriate patients are included in research studies. This protects both the patients and the integrity of the scientific findings.5

The standard requirement for entering most Ebola treatment trials is laboratory confirmation that the patient is actively infected with one of the viruses that cause Ebola disease. This is almost always done using the RT-PCR blood test, which must show a positive result for the virus's genetic material. The test not only confirms the diagnosis but can also identify which specific type of virus is causing the infection. There are four main types of orthoebolaviruses that cause illness in people: Ebola virus (the most common), Sudan virus, Bundibugyo virus, and Taï Forest virus. Knowing which type is present is important because some treatments and vaccines only work against certain virus types.1

Clinical trials often measure the amount of virus in the blood, which is called the viral load. This measurement helps researchers understand how severe the infection is and whether the experimental treatment is reducing the amount of virus over time. Patients with very high viral loads may be at greater risk of serious complications or death, and viral load measurements can help predict outcomes. During the trial, doctors will repeat these tests at regular intervals to track whether the treatment is working.5

In addition to confirming Ebola virus infection, clinical trials require baseline health assessments before any experimental treatment begins. These typically include blood tests to check liver and kidney function, blood cell counts, and tests for other infections that might affect how the patient responds to treatment. For example, testing for malaria is often performed since malaria is common in regions where Ebola occurs, and having both infections at once can complicate treatment and recovery.2

Patients entering clinical trials also need tests to measure vital signs and organ function. This includes checking blood pressure, heart rate, breathing rate, and body temperature. Doctors may also assess signs of dehydration and malnutrition, which are common in Ebola patients due to vomiting and diarrhea. All of these measurements provide a starting point that researchers can compare to later results to see if the experimental treatment is helping.5

Some clinical trials focus on preventing Ebola disease rather than treating active infections. These vaccine trials typically enroll people who have been exposed to Ebola but have not yet developed symptoms. For these participants, diagnostic testing confirms that they do not have Ebola virus in their blood at the start of the study. They are then monitored closely for the 21-day incubation period, with repeated testing if any symptoms develop. This approach helps researchers determine whether the vaccine successfully prevented infection after exposure.5

During the West Africa outbreak between 2014 and 2016, several clinical trials were conducted to test new treatments. One important study, called the PALM trial, tested four different treatments in the Democratic Republic of the Congo. To enter this trial, patients needed a confirmed Ebola diagnosis by RT-PCR, and they had to be well enough to provide informed consent or have a family member provide consent on their behalf. The trial measured outcomes such as viral load changes, survival rates, and time to recovery. Through careful diagnostic testing and monitoring, researchers were able to identify two treatments that significantly improved survival, which were later approved for use.5

Prognosis and Survival Rate